Tehran’s tactical knockout: Weaponized pharmaceutical-based agents

As early as the 1980s, the U.S. intelligence community documented the ways in which Iran deployed chemical weapons for tactical delivery on the battlefield. 

Nearly 40 years later, U.S. officials formally assessed that Iran was in non-compliance with its Chemical Weapons Convention (CWC) obligations, pointing specifically to Tehran’s development of pharmaceutical-based agents (PBAs) that attack a person’s central nervous system as part of a chemical weapons program. 

Over time, concern about this program has increased, with reports to the Organisation for the Prevention of Chemical Weapons (OPCW), statements by multilateral groups such as the G7, and a variety of U.S. government reports and sanctions. 

Today, with Iran’s proxies wreaking havoc throughout the region, officials worry Tehran may have already provided weaponized PBAs to several of its partners and proxies. 

Such a capability, tactically deployed on the battlefield, could enable further October 7-style cross-border raids or kidnapping operations. 

With the region on edge following the targeted killing of Hezbollah leader Hassan Nasrallah, followed by an Israeli ground campaign targeting Hezbollah infrastructure along the border, and the Iranian ballistic missile attack on Israel, concern about the use of such tactical chemical weapons is high.

Read the full report